{"entity":{"id":"amphista-therapeutics","kind":"company","name":"Amphista Therapeutics","aka":[],"tldr":"Amphista Therapeutics, based near Cambridge in the UK, designs small molecules that make cancer cells destroy specific proteins using a less common disposal enzyme called DCAF16. Its first drug, for acute myeloid leukaemia, was cleared to start human trials in 2026.","summary":"Amphista Therapeutics is a Cambridge, UK targeted protein degradation company whose Targeted Glue degraders deploy E3 ligases beyond cereblon, such as DCAF16, chosen for each target. Its lead programme, AMX-883, is an orally bioavailable, selective DCAF16-mediated BRD9 degrader for acute myeloid leukaemia that releases the differentiation block in a broad AML population, shows in vivo efficacy alone and synergy with venetoclax, and received FDA clearance of its IND application in June 2026 as the first BRD9-targeted therapy for AML. An oral SMARCA2 Targeted Glue degrader targets SMARCA4-deficient tumours including non-small cell lung cancer through synthetic lethality, and a pan-TEAD degrader targets Hippo pathway-driven cancers such as mesothelioma and NSCLC; both are preclinical, with data presented at AACR 2026. The company is registered in England and Wales (number 11119959) with its head office at Granta Park, Great Abington, Cambridge.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://amphista.com/"},{"label":"Pipeline","url":"https://amphista.com/pipeline/"},{"label":"AMX-883 IND clearance (June 2026)","url":"https://amphista.com/amphista-therapeutics-announces-fda-clearance-of-ind-application-for-amx-883-its-lead-targeted-glue-degrader-for-acute-myeloid-leukaemia/"}],"tags":[],"related":[],"cancers":["aml","nsclc","mesothelioma"],"sections":["targeted-therapy","epigenetics"],"technologies":["protac-degrader","epigenetic-drugs","synthetic-lethality-approaches"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No financing press release is on the company's current news page (which lists 2026 items only), so funding and investors are empty; the reported 2021 Series B and Merck and Bristol Myers Squibb collaborations were not verified. Founding year not sourced."],"hq":"Cambridge","country":"GB","companyType":"biotech","website":"https://amphista.com/","stage":"startup","investors":["novartis-venture-fund"],"funding":[]},"route":"/companies/amphista-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","route":"/fronts/epigenetics/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"company":[{"id":"novartis-venture-fund","kind":"company","name":"Novartis Venture Fund","route":"/companies/novartis-venture-fund/"}]}}